Human Hox genes (Homeobox) have crucial roles in development and differentiation, regulating numerous processes including apoptosis, receptor signalling, differentiation, motility and angiogenesis. Aberrant expression of Hoxc6 gene has been reported in several tumor tissues and cancer cell lines. The prognostic significance of Hoxc6 in gastric cancer remains largely unknown.This study was aimed to investigate the clinical significance of Hoxc6 in gastric cancer.
some tumors, aberrant Hox gene expressions directly drives tumorigenesis through escape from apoptosis [10] , alterations to receptor signalling [11] , tumor cell invasion [12] , and epithelial-mesenchymal transition (EMT) [13] .
Hoxc6 that is localized on chromosomes 12q13.3 shares a 5' non-coding exon with Hoxc5 and Hoxc4, upregulation of Hoxc6 has been reported in some tumors, such as osteosarcoma [14] , neuroblastoma [15] , breast cancer [16] , lung cancer [17] and prostate cancer [18] .
Gastric cancer is one of the most common malignant tumors and the second leading cause of cancer mortality worldwide. Although the decline in the incidence during the past decade, gastric cancer remains a major health problem because of the slow incidence decline in Asia and high mortality in the west [19] [20] [21] . Gastric cancer is usually detected at an advanced stage in many patients with lymph node invasion and metastasis. Despite a curative operation and postoperative adjuvant therapy, nearly 60% of those patients die of this fatal disease [22] [23] [24] . The total prognosis of gastric cancer is still poor [25] . Currently, the tumor (T) node (N) metastasis (M) stage is still the most important prognostic factor for gastric cancer. Prognosis often varies among patients in the same stage [26] . Therefore, identification of reliable molecular targets in chemotherapy of gastric cancer is very important [27 ] .
There has not been reported whether or not Hoxc6 gene is aberrantly expressed in gastric epithelial neoplasms. The present study examined Hoxc6 mRNA and protein expressions in gastric cancer specimens and evaluated clinicopathological significance and prognostic value of Hoxc6 expression in gastric cancer patients to determine the possible use of Hoxc6 as a prognostic molecular marker in gastric cancer. [28] . None of the patients had received radiotherapy or chemotherapy prior to surgery, Patients with advanced gastric cancer received standard chemotherapeutic protocols, including 5-fluorouracil postoperatively, according to the NCCN Practice Guidelines for Gastric Cancer [29] . All patients were subjected to close follow-up observation. The follow-up deadline was October 2010.
Materials and methods

Patients
For tissue microarray (TMA) construction, formalin-fixed, paraffin-embedded samples from above 161 patients that contained primary tumors and adjacent normal mucosa were retrieved from the archives of the Department of Pathology in Ruijin Hospital. Hematoxylin and eosin (H&E)-stained slides were screened for tumor tissue and non-cancerous tissue adjacent to tumor (at least 2 cm from the tumor). Representative areas of tissue were established and 2.0-mm diameter cores were punched from the paraffin blocks. Two cores from each tumor and paired normal tissue (at least 2 cm from the tumor) were arrayed next to each other to ensure similar reaction conditions. All specimens were examined by two pathologists to prevent bias. Tumor and normal mucosa morphology on the arrays were validated as having high accordance with the whole archived section. TMA slides were constructed and made in collaboration with Shanghai Biochip (Shanghai, P. R. China).
Quantitative real-time PCR. Total RNA in 25 paired, frozen primary gastric cancer tissues, and adjacent normal mucosa were extracted according to the manufacturers instructions (Life Technologies, CA,USA, and then 0.5 μg RNA was reverse transcribed into cDNA using a PrimerScript™ RT reagent kit (Takara Bio Inc., Dalian, China). qPCR was performed in a 10ml total reaction mixture. Quantitative Hoxc6 mRNA levels were assessed by using ABI 7500 real-time PCR System (Applied Biosystems, Carlsbad, CA) with a Master Mix kit (Takara Bio Inc.,Dalian, China) according to the manufacturer's protocol. GAPDH was used as an internal control. adjacent noncancerous mucosa was significant(47.2% vs 18% P <0.05. Figure 2) . Associations between clinicopathological factors and Hoxc6 expression are summarized (Table 2) . Each Real-time PCR was repeated 3 times, 2-ΔΔCt method was used for normalization with GAPDH as reference gene. Gene expression with a ratio of more than 2 was considered to be upregulated. The sequences for qRT-PCR primers were as follows: GAPDH forward:TGTTGCCATCAATGACCCCTT GAPDH reverse:CTCCACGACGTACTCAGCG HOXC6 forward: CCCCACCAACTCTCCCCTAA HOXC6 reverse:CAGGTCCACGTTTGACTCCC Immunohistochemistry. The TMA sections were deparaffinized in xylene and rehydrated in graded series of ethanols followed by heat-induced epitope retrieval in citrate buffer (pH 6.0). Hoxc6 expression were detected using a primary antibody against HOXC6 (Anti-Hoxc6 antibody produced in rabbit, Sigma.USA). After incubation with a biotinylated secondary antibody and DAB (Dako), the slides were rinsed and counterstained with Mayer's hematoxylin. Staining was scored by two independent investigators without knowledge of patient.outcomes according to the staining intensity and extent as described previously [30] . To evaluate Hoxc6 expression, immuostaining was classified into the following four groups according to both intensity and extent. The proportion of cells proteins expression was categorized as follows: 0, 0% immunopositive cells; 1, <10% positive cells; 2, 11~50% positive cells; 3, 51~75% positive cells; and 4, >75% positive cells. The staining intensity was categorized by relative intensity as foll-ows: 0, negative; 1, weak; 3, moderate; 4, strong. The proportion and intensity scores were then multiplied to obtain a total score. To obtain final statistical results, scores less than 2 was considered as negative, while scores of 3~4 were considered as(+), scores of 5~8 as(++), scores of 9~12 as(+++).
Statistical analysis. Statistical analysis was performed using SPSS 17.0 statistical software (Chicago, IL, USA) . Correlation was assessed with the Spearman rho correlation coefficient and Pearson chi-square test. Kaplan-Meier survival curves were generated and survival data were analyzed with the log-rank test. P values < 0.05 were considered statistically significant.
Results. Up-regulation of Hoxc6 expression in primary gastric cancer tissues compared with adjacent normal mucosa. Of the 25 paired cases used for the evaluation of Hoxc6 mRNA, 16 (64%) gastric cancer tissues showed at least a twofold increase in Hoxc6 mRNA level compared with the adjacent noncancerous mucosa (Figure1). The difference in Hoxc6 mRNA expression was significant (64% vs 36% P< 0.05).
Association of Hoxc6 TMA immunohistochemical staining with patient clinicopathological parameters. Expression of Hoxc6 was predominantly localized in the nuclei and cytoplasm of tumor cells. Of the 161 TMA tumor specimens, Expression of Hoxc6 was observed in 76 (47.2 %) of tumors .Among them, 70 cases with a score of + , 6 cases with a score of ++ respectively. Meanwhile, 29 of 161 (18%) adjacent noncancerous tissues displayed positive staining, they could only be detected in adjacent dysplastic mucosa. Among them, 19 cases with a score of + , 10 cases with a score of ++ respectively. The difference in Hoxc6 expression between tumor cells and Increased Hoxc6 expression was significantly correlated with the depth of tumor invasion (P< 0.05. Table 2) .
Survival analysis and prognostic significance of Hoxc6 expression. Kaplan-Meier curves showed that patients with positive Hoxc6 expression had a lower overall survival rate than did the group with negative Hoxc6 expression (P <0.05. Figure 3) .
Discussion. It is evident that many of the molecular pathways that are involved in carcinogenesis represent aberrations of the normal processes that control embryogenesis. There are many examples in which the abnormal expression of genes that regulate growth and development have been involved in carcinogenesis. Among them the principal examples are Homeobox genes [1] , Hox genes, a highly conserved subgroup of the homeobox superfamily, have crucial roles in development and differentiation. Aberrations in Hox gene expression have been reported in abnormal development and malignancy, therefore, Hox gene expression could be important in diagnosis and therapy in malignancy [31] .
Normal Hox gene expression is disrupted and affects various pathways that promote tumorigenesis and metastasis. In some tumors, organogenesis pathways, such as receptor signalling pathways, are altered and drive tumor growth. At other times, Hox gene expression is altered and results in the maintenance of a more embryonic state through the activation of anti-apoptotic pathways or suppression of differentiation. Additionally, new mechanisms, such as protein-protein interactions, might also enable Hox proteins to maintain an oncogenic capacity [31] .
Hoxc6 directly regulates expression of bone morphogenic protein 7, fibroblast growth factor receptor 2, insulin-like growth factor binding protein 3, and platelet-derived growth factor receptorα ( PDGFRA) in prostate cells and indirectly influences the Notch and Wnt signaling pathways in vivo, inhibition of PD-GFRA reduces proliferation of prostate cancer cells, and that overexpression of Hoxc6 can overcome the effects of PDGFRA inhibition. Through above mechanisms, transcriptional network regulated by Hoxc6 plays crucial roles in proliferation, survival, and metastasis of prostate cancer cells [32] . In cultured human BON1 carcinoid cells, expression of Hoxc6 enhanced their proliferation,and knockdown of Hoxc6 inhibited their growth. Hoxc6 activated the oncogenic activator protein-1 signaling pathway through a physical interaction with JunD. Mutations in the homeodomain of Hoxc6 blocked this interaction and inhibited proliferation of carcinoid cells. Moreover, Hoxc6 induced the expression of genes that characteristically are up-regulated in carcinoid tumors, including neurotensin and connective tissue growth factor [33] .
The aim of postoperative chemotherapy is to treat residual micrometastases after surgical resection to improve survival. Ideally, rational chemotherapy should be given to patients with high risk of recurrence and metastasis. However, it remains a great challenge to accurately predict outcome for each gastric cancer patient so that it will be easy to determine who will benefit from adjuvant therapy. Gastric cancer is highly heterogeneous, traditional prognostic factors such as TNM staging system is sometimes less predictive of outcome, particularly within the same stages of the disease, as a result, many patients receive unnecessary or insufficient adjuvant treatment which might be both harmful.
In our study, Hoxc6 protein was detected expressed in gastric cancer and dysplastic mucosal tissues, no Hoxc6 expression could be found in normal gastric mucosal cells. It is likely that Hoxc6 has been implicated in the pathogenesis of gastric cancer. The mechanism by which Hoxc6 involves in tumorigenesis remains to be investigated.
The expression of human Hoxc6 together with its correction of clinicopathological parameters in gastric epithelial neoplasms has not been reported before. In this study, we explored Hoxc6 gene mRNA and protein expressions in normal and malignant gastric tissues and we found Hoxc6 mRNA and protein had higher expression levels in cancer tissue than in its adjacent normal tissue, suggesting upregulation of Hoxc6 occurred at the transcriptional as well as posttranscriptional level. Our results showed that increased Hoxc6 expression was significantly correlated with the depth of tumor invasion, which hinted Hoxc6 expression may be associated with the development of gastric cancer. Our study also found that patients with positive Hoxc6 expression had a lower overall survival rate than did the group with negative Hoxc6 expression, so it would contribute to identify high risk patients who should receive more aggressive adjuvant chemotherapy, thus low risk patients receive less after potentially curative surgery. It also suggested that Hoxc6 could be a potential therapeutic target in the molecular pathways determining the behavior of gastric cancer.
These preliminary findings need to be verified in a larger, prospective, controlled clinical study, The mechanism by which Hoxc6 is involved in tumorigenesis and cancer progression has not been elucidated yet.
